RE: Is it time to reconsider the role of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma?

J Natl Cancer Inst. 2024 Sep 1;116(9):1534. doi: 10.1093/jnci/djae158.

Authors

Jaleh Fallah¹, Haley Gittleman¹, Chana Weinstock¹, Elaine Chang¹, Sundeep Agrawal¹, Shenghui Tang¹, Richard Pazdur^{1

2}, Paul G Kluetz^{1

2}, Daniel L Suzman¹, Laleh Amiri-Kordestani^{1

2}

Affiliations

¹ Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
² Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA.

PMID: 38950174
DOI: 10.1093/jnci/djae158

No abstract available

Publication types

Letter

MeSH terms

Carcinoma, Renal Cell* / pathology
Carcinoma, Renal Cell* / secondary
Carcinoma, Renal Cell* / surgery
Cytoreduction Surgical Procedures* / methods
Humans
Kidney Neoplasms* / pathology
Kidney Neoplasms* / surgery
Nephrectomy* / methods